Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Real-time Estimate Cboe BZX
Other stock markets
 02:40:05 2024-05-28 pm EDT 		5-day change 1st Jan Change
1.895 USD -1.81% Intraday chart for Xeris Biopharma Holdings, Inc. -4.25% -18.51%
May. 09 Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target
MT
Craig-Hallum Initiates Xeris Biopharma Holdings at Buy Rating With $4.50 Price Target
MT
SVB Securities Trims Xeris Biopharma Price Target to $5 From $6, Maintains Outperform Rating
MT
Jefferies Starts Xeris Biopharma Holdings at Buy With $4 Price Target
MT
Craig-Hallum Starts Xeris Biopharma Holdings at Buy With $6.50 Price Target
MT
Mizuho Securities Adjusts Xeris Biopharma Holdings' Price Target to $6 From $8, Keeps Buy Rating
MT
SVB Leerink Adjusts Xeris Biopharma Holdings Price Target to $6 From $8, Maintains Outperform Rating
MT
SVB Leerink Raises Price Target on Xeris Biopharma Holdings to $8 From $6, Maintains Outperform Rating
MT
HC Wainwright Raises Price Target on Xeris Biopharma Holdings to $5.40 From $4.25, Maintains Buy Rating
MT
SVB Leerink Starts Xeris Pharmaceuticals at Outperform With $6 Price Target
MT
HC Wainwright Starts Xeris Pharmaceuticals at Buy With $4 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XERS Stock
  4. News Xeris Biopharma Holdings, Inc.
  5. Analyst Reco.